Over the past six months, search volume for menopause support has fallen 30.1%, and consumer conversation about it has dropped by half, the steepest decline of any women’s wellness benefit CPG Radar tracks.
It would be easy to read that as a cooling market. It is not. The hot flashes have not stopped and neither has the search for relief. What has changed is the language women use to look for it and the growing distance between how they describe their experience and how the category describes its products. That distance, measured across search behavior, consumer reviews and clinical literature, is where the next round of menopause innovation will be decided.
The need did not shrink. It moved.
While conversation around menopause support fell 50%, conversation around hormonal balance rose 233%, the fastest growth of any sub-benefit in the women’s wellness data. The same women, with the same symptoms, are increasingly framing the problem as one of balance rather than life stage.
The shelf has not followed them. Menopause support is one of the more concentrated corners of women’s wellness, with a handful of established positions and ingredients doing most of the work. Hormonal balance is roughly four times less concentrated. For a formulator, that combination is unusual: demand growing quickly into a space where no one has yet claimed the defining position. Brands still competing under the menopause banner are fighting harder over a conversation that is shrinking, while the conversation that is growing remains comparatively open.
Women talk about symptoms. Brands talk about estrogen.
Read what women actually write about menopause products, and three patterns emerge. The most common is physical and vivid: hot flashes, night sweats, the difference between waking up soaking wet and sleeping through a dry night. The second is blunt and binary. A product either worked or it “did absolutely nothing,” and when it did nothing, it was abandoned. The third is smaller but growing: women tracking their own lab values, reporting progesterone and testosterone readings and expecting products to move them.
Almost none of that language starts with estrogen. Yet estrogen is where the category’s marketing begins. The dominant narrative positions plant compounds as a gentler alternative to hormone replacement therapy, built on the idea of mimicking the body’s own hormones or acting on the brain’s temperature regulation. It is a mechanism story told to a consumer who is asking a relief question. She wants to know whether she will sleep through the night. The category answers by explaining what the ingredient resembles.
The category’s anchor is trusted beyond its evidence
Black cohosh is the ingredient women know and the one the category leans on most. Its clinical record is respectable. On CPG Radar’s evidence scoring, it lands at 46, in the emerging tier, but short of the 60-plus threshold that would match its dominance on shelf. Relative to the strength of its evidence, black cohosh carries roughly five times the brand presence it can comfortably support, the same imbalance seen in ashwagandha.
Inositol offers the contrast. It scores 71 on evidence and appears in 138 brands, a ratio that leaves its claims on firmer footing. The lesson is not that black cohosh should be abandoned. Women already trust it, and that trust is hard to build from scratch. The opportunity is a better-substantiated version of the ingredient she already recognizes, rather than a new ingredient she has to be taught to believe in.
The fear is the liver. The complaint is the gut.
Black cohosh has carried a hepatotoxicity concern for years, and much of the category’s safety messaging is still shaped by it. The clinical picture is more reassuring than the reputation. A meta-analysis of randomized controlled trials on the isopropanolic extract found no evidence supporting liver harm.
What women actually complain about is gastrointestinal: bloating, gas and digestive urgency that product messaging rarely mention. One reviewer put it plainly, noting that none of the sites recommending black cohosh for hot flashes had warned her about the bloating. That gap matters more than it appears. A side effect nobody mentioned does not just cost a reorder. It makes her question everything else the label told her. Tolerability, in this category, is a trust claim as much as a safety claim, and a standardized extract or ingredient pairing that resolves it addresses the friction women actually report rather than the fear the science has already put to rest.
She is buying out of urgency, not curiosity
The core buyer in this category is not browsing wellness trends. She is looking for relief from symptoms she often finds embarrassing, from hot flashes to urogenital changes, and she wants it quickly. Her priorities follow from that: formats that are easy to swallow, a single daily dose, rapid onset and enough clinical credibility to justify the purchase. She is also the shopper most strongly drawn to black cohosh, showing more than twice the affinity for it of the average buyer.
Online conversations show how quickly her verdict forms. The same category produces women who felt like themselves again within a week and women who finished a full 30-day supply with nothing to show for it. Trust does not follow the claim on the label. It follows how her body responds, and how fast. For this buyer, fast, well-tolerated relief will beat a more elaborate ingredient story every time.
Mimicry versus metabolism
There are two broad ways a supplement can influence estrogen activity. The familiar one is mimicry. Phytoestrogens are absorbed, some are converted by gut bacteria into more active forms such as equol, and they bind estrogen receptors with a weak estrogen-like or blocking effect. Black cohosh, notably, is not a phytoestrogen, though it is often marketed alongside them. In either case, the product lever is the dose of an active compound.
The less familiar route runs through the estrobolome, the set of gut bacteria that influence how the body recycles its own estrogen. The liver inactivates estrogen and sends it to the gut in bile for disposal. Bacterial enzymes, chiefly beta-glucuronidase, can reactivate some of it, allowing it to be reabsorbed rather than excreted. Here the product lever is not a compound’s dose but the activity of the microbes doing the recycling.
That distinction gives the category something it currently lacks: a credible metabolism story that connects naturally to the hormonal balance language women are already using. The good news? Ingredient suppliers have started to launch estrobolome-centric technologies with encouraging clinical evidence that’s starting to emerge in market. As with any claim in this space, how that evidence translates to the label is a question for regulatory counsel, but it shows the metabolism route is no longer theoretical.
Closing the gap
The menopause category does not have a demand problem. It has a translation problem. Women describe relief they can feel; brands describe mechanisms they cannot see. The opportunities that follow sit on two horizons.
In the near term, the strongest move is a credibility upgrade rather than a new ingredient. A strictly standardized black cohosh extract or marrying black cohosh with a GI-centric ingredient built around the GI tolerability women actually complain about keeps the story she already believes while closing the evidence gap behind the category’s most crowded ingredient. Over the longer term, the larger prize is the hormonal balance conversation, which is growing fast on a shelf that has not yet consolidated. Winning it will require more than new vocabulary. It will require a mechanism that can carry the claim, and estrogen metabolism through the gut is among the most credible candidates.
In both cases, the formula for trust is the same: Lead with the relief she is looking for, and back it with science she can believe.
The data behind this analysis is tracked continuously inside CPG Radar’s Signals platform, which is what made it possible to see the gap between consumer language and brand messaging in the first place.
Afif Ghannoum, CEO of CPG Radar, hosted a webinar with a deeper dive into this analysis, including a fireside discussion regarding formulating for the estrobolome. Register here to view the on-demand webinar, “The Menopause Gap: What Women Say vs. What Brands Claim.”
